Garcinone D: A Comprehensive Encyclopedic Reference
1. Identity: Chemical and Botanical Classification
Chemical Identity
Garcinone D is a xanthone — a class of natural polyphenolic compounds — with diverse biological activities. Its Chemical Abstracts Service (CAS) registry number is 107390-08-9. Xanthones share a distinctive tricyclic aromatic ring system (dibenzo-γ-pyrone backbone), and garcinone D belongs specifically to the prenylated subclass, meaning it carries isoprenoid (prenyl) side chains on the aromatic ring system. This class of xanthones is "largely responsible for its biological activities."
Prenylated xanthones isolated from Garcinia mangostana have been extensively studied; some members of these compounds possess antioxidant, antitumoral, antiallergic, anti-inflammatory, antibacterial, antifungal, and antiviral properties. Xanthones have been isolated from the pericarp, whole fruit, heartwood, and leaves of the plant.
Natural Sources
Garcinone D is a natural xanthone from mangosteen (Garcinia mangostana L.). Garcinia mangostana Linn. (GML) belongs to the family Guttiferae (also classified as Clusiaceae) and is named "the queen of fruits"; it is cultivated in the tropical rainforest of some Southeast Asian nations like Indonesia, Malaysia, Sri Lanka, the Philippines, and Thailand.
Beyond the primary source, garcinone D has been isolated from additional species within the Garcinia genus. Phytochemical investigation of a dichloromethane extract from the roots of Garcinia cowa led to the isolation of garcinone D as one of nineteen known xanthones alongside newly discovered compounds. Garcinone D has also been recovered from the pericarps of G. mangostana in multiple independent investigations. An ethanol extract of the pericarps subjected to silica gel column chromatography followed by repeated HPLC yielded garcinones C and D, gartanin, xanthone I, and γ-mangostin, among others.
Garcinone D has also been isolated from the stem bark of G. mangostana, specifically identified as compound 7 alongside ten other known xanthones including α-mangostin, β-mangostin, and 8-deoxygartanin.
Position Among the Garcinone Series
Garcinone D is one member of a named series of xanthones from the Garcinia genus. Three new tetraoxygenated xanthones (garcinones A, B, and C), each disubstituted with C5-units, were originally isolated from the chloroform extract of the fruit-hulls of Garcinia mangostana. Garcinones D and E were characterized in subsequent investigations. The most studied xanthones from this species are α-, β-, and γ-mangostins, garcinone E, 8-deoxygartanin, and gartanin, with garcinone D receiving comparatively less dedicated study but appearing as a co-isolated compound in numerous phytochemical investigations.
Common Forms and Preparations
Garcinone D is not typically available as an isolated, standalone dietary supplement ingredient. It is encountered in two principal contexts: (1) as a purified reference standard or research compound for laboratory use (typically supplied at ≥95% purity by chemical reagent companies); and (2) as one component of the complex xanthone mixture present in whole mangosteen pericarp-based products, which are commercially available as dried pericarp powder, encapsulated extracts, juices, and mixed fruit beverages. The seeds and pericarps of the fruit have a long history of use in the traditional medicinal practices of the region, and beverages containing mangosteen pulp and pericarps are sold. Individual garcinone D content in commercial whole-pericarp preparations is not standardized and varies by product and extraction method.
2. Traditional and Historical Use
Southeast Asian Ethnomedicinal Context
Based on written historical records, linguistic evidence, and field observations, mangosteen is speculated to have originated in the everwet zones of Southeast Asia, including Sumatra, the Malay Peninsula, and Borneo. The fruit is often dubbed the "Queen of Fruits."
People in Southeast Asian countries have used the pericarp (peel, rind, hull) of G. mangostana as a traditional medicine for the treatment of abdominal pain, diarrhea, dysentery, infected wounds, suppuration, and chronic ulcer. With a sweet and tangy flavor, the fruit's white aril is commonly consumed fresh, whereas the bitter pericarp is applied in traditional Southeast Asian remedies for ailments ranging from gastrointestinal issues, like abdominal pain and diarrhea, to skin conditions, such as infected wounds and chronic ulcers. The traditional use of the mangosteen pericarp in treating infected wounds and ulcers implies a role in modulating local immune responses and inflammatory processes.
Garcinia mangostana L. (Mangosteen) has been used to treat various pathological conditions, including inflammation and urinary tract infections.
Important Distinction: Traditional Use and Garcinone D Specifically
It is critical to note that none of the traditional ethnomedicinal literature identifies garcinone D as such. The compound was not isolated and characterized until modern phytochemical research. The medicinal value of mangosteen pericarp is primarily attributed to its abundance of xanthones, especially prenylated derivatives, which exhibit diverse pharmacological applications. Garcinone D is one among this complex mixture of xanthones, and traditional preparations would have contained it alongside α-mangostin, β-mangostin, γ-mangostin, garcinone E, gartanin, and numerous other co-occurring compounds. All attributions of traditional use therefore apply to the whole pericarp or its extracts, not to isolated garcinone D.
Use in Other Garcinia Species Traditions
Garcinia hanburyi and G. schefferi have been traditionally used as medicinal plants in China; these uses result from the exchange and sharing of traditional medicinal practices with people in Southeast Asia. Recent phytochemical and pharmacological studies have revealed that extracts or biochemical constituents such as xanthones and benzophenones from Garcinia species possess various pharmacological activities, including anticancer and antidiabetic effects, indicating the therapeutic potential of G. mangostana fruits as food supplements for human health.
3. Key Constituents and Chemical Context
The Xanthone Class
Mangosteen is a tropical fruit native to Southeast Asia and is an abundant source of xanthones, a class of polyphenolic compounds with a distinctive tricyclic aromatic ring system, largely responsible for its biological activities including anti-cancer activity. Garcinone D is classified as a prenylated xanthone, a structural subtype characterized by the presence of one or more 3-methylbut-2-en-1-yl (prenyl) substituents on the xanthone skeleton. These prenyl groups are understood to modulate membrane permeability and biological interactions.
Co-Occurring Xanthones
From the pericarp of G. mangostana, garcinone D has been identified alongside cudraxanthone G, 8-deoxygartanin, garcimangosone B, garcinone E, gartanin, 1-isomangostin, α-mangostin, γ-mangostin, mangostinone, smeathxanthone A, and tovophyllin A. This complex chemical milieu is important for understanding product-level research: studies on mangosteen products report the collective activity of this mixture rather than garcinone D alone.
4. Scientific Evidence by Area of Use
4.1 Anticancer / Cytotoxic Activity
Colon Cancer (HT-29 Cell Line)
Bioassay-guided fractionation of a chloroform-soluble extract of Garcinia mangostana stem bark, using the HT-29 human colon cancer cell line and an enzyme-based ELISA NF-κB assay, led to the isolation of garcinone D alongside ten other known compounds. Compounds 4–8 from this isolation, which includes garcinone D (compound 7), exhibited cytotoxicity against the HT-29 cell line with ED₅₀ values of 4.9, 1.7, 1.7, 2.3, and 9.1 μM, respectively. Specifically, in an ELISA NF-κB assay, compounds 5–7, 9, and 10 (including garcinone D as compound 7) inhibited p65 activation with IC₅₀ values of 15.9, 12.1, 3.2, 11.3, and 19.0 μM, respectively.
Compounds 4, 7, and 8 (garcinone D being compound 7) have also been reported for their cytotoxicity against epidermoid carcinoma (KB), breast cancer (BC-1), or small cell lung cancer (NCI-H187).
Evidence strength: Preclinical, in vitro only. No clinical (human) data available for this specific compound in oncology.
HeLa Cervical Cancer Cells
In a cytotoxicity assay against HeLa cancer cells, garcinone D demonstrated an IC₅₀ value of 11.96 μM, placing it among a series of Garcinia xanthones with moderate-to-strong anti-HeLa activity. This was assessed alongside compounds such as rubraxanthone (IC₅₀ 7.85 μM) and cowanol (IC₅₀ 12.19 μM) from Garcinia cowa.
Evidence strength: Preclinical, in vitro only.
Aromatase Inhibition (Breast Cancer Relevance)
Twelve xanthone constituents of mangosteen pericarp were screened using a noncellular, enzyme-based microsomal aromatase inhibition assay; of these compounds, garcinone D, garcinone E, α-mangostin, and γ-mangostin exhibited dose-dependent inhibitory activity. IC₅₀ curves for active compounds from this study identified garcinone D (compound 3) as having an IC₅₀ of 5.16 μM in the microsomal aromatase inhibition assay. In a follow-up cell-based assay using SK-BR-3 breast cancer cells that express high levels of aromatase, the most potent of these four xanthones was γ-mangostin (9), with garcinone D being less potent in this cellular context.
Because xanthones may be consumed in substantial amounts from commercially available mangosteen products, the consequences of frequent intake of mangosteen botanical dietary supplements require further investigation.
Evidence strength: Preclinical; enzyme-based and cell-based assays only. No human clinical data on aromatase-related outcomes specific to garcinone D.
Cytotoxic Prenylated Xanthone Isolation from Pericarps
From a fractionation of the ethanol extract of G. mangostana pericarps, garcinones C and D were co-isolated with two new prenylated xanthone derivatives; all compounds showed significant cytotoxic activities against various human cancer cell lines.
4.2 Anti-Inflammatory Activity
A recent study isolating compounds from the pericarp of Garcinia mangostana — obtaining three new compounds (garcimangone A, B, and the S-form of garcimangone C) alongside 18 known compounds — found that γ-mangostin, garcinone D, morusignin J, and fuscaxanthone C showed the most potent NO-inhibitory effects in LPS-stimulated RAW264.7 macrophage cells. Structure-activity relationship study revealed that a chromeno moiety at C-3,4, oxygen substituents at C-1,3,6,7, and isoprenyl groups at C-2,8 are key structural features that promote anti-inflammatory activity.
This NO-inhibitory activity in macrophages is consistent with the broadly observed anti-inflammatory profile of prenylated mangosteen xanthones. Studies have shown that extracts of mangosteen pericarp have many biological functions, such as anti-oxidation, anti-inflammation, and anti-microbial activity.
Evidence strength: Preclinical, in vitro (cell-based macrophage assay) only. No clinical human trials on garcinone D's isolated anti-inflammatory activity.
4.3 NF-κB Pathway Inhibition
Garcinone D's most consistently reported mechanism of action in cancer-related studies is the inhibition of nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB). In an ELISA NF-κB assay conducted on compounds from G. mangostana stem bark, garcinone D inhibited NF-κB p65 subunit activation with an IC₅₀ of 3.2 μM — the most potent NF-κB p65 inhibitor among the ten compounds tested in that study. NF-κB is a transcription factor regulating genes involved in cell survival, proliferation, and inflammation; its inhibition is considered a relevant mechanistic target in both oncology and inflammatory disease research.
Evidence strength: Mechanistic, in vitro only.
4.4 Neuroprotective Activity and Alzheimer's Disease Research
Amyloid-Beta Aggregation Inhibition
A series of xanthones isolated from the pericarps of Garcinia mangostana Linn, including α-Mangostin, 8-Deoxygartanin, Gartanin, Garciniafuran, Garcinone C, Garcinone D, and γ-Mangostin were investigated; biological screening performed in vitro and in Escherichia coli cells indicated that most of the xanthones exhibited significant inhibition of self-induced β-amyloid (Aβ) aggregation and also β-site amyloid precursor protein-cleaving enzyme 1 (BACE1), and acted as potential antioxidants and biometal chelators.
Protection Against Aβ42-Induced Neurotoxicity
Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterized by the accumulation of Aβ42 peptides, which contribute to oxidative stress, apoptosis, and mitochondrial dysfunction in neurons. Garcinone D (GD), a bioactive xanthone derived from mangosteen, has shown promise as a neuroprotective agent; however, its mechanisms of action against Aβ42-induced neurotoxicity remain insufficiently defined. One study examined the protective effects of GD in Aβ42-treated neuronal cells, focusing on key molecular pathways. The results demonstrated that GD significantly enhances cell viability and stabilizes mitochondrial function while reducing reactive oxygen species and apoptotic markers in Aβ42-treated cells; additionally, GD activates key antioxidant pathways involving Nrf2 and HO-1, and inhibits caspase activity, thereby demonstrating a multifaceted approach to neuroprotection.
In a prior related study, garcinone D was found to inhibit Aβ42 aggregation. These findings suggest that GD could serve as a valuable therapeutic candidate for AD by addressing multiple aspects of cellular damage that contribute to neurodegeneration. By promoting mitochondrial health while modulating oxidative and apoptotic pathways, GD shows potential for advancing therapeutic strategies in neurodegenerative disorders.
Evidence strength: Preclinical, in vitro (cell-based neuronal models) only. No human clinical data exist for garcinone D in Alzheimer's disease or neurodegenerative conditions.
Neural Stem Cell Proliferation
Garcinone D, a natural xanthone from mangosteen, was observed to promote the proliferation of C17.2 neural progenitor cells and resulted in a larger percentage of cells in S phase compared with the control group. Garcinone D increased the protein levels of phosphorylated STAT3 (p-STAT3) and Cyclin D1 in concentration- and time-dependent manners. Garcinone D also increased the protein levels of Nrf2 and HO-1 in concentration- and time-dependent manners, and inhibiting Nrf2 activation by brusatol could partly reverse garcinone D-induced C17.2 cell proliferation.
The authors noted that further study should be necessary to prove its role in neural stem cells in vivo.
Evidence strength: Preclinical, in vitro (murine neural stem cell line). Not yet validated in vivo or in human tissue.
4.5 Antioxidant Activity
Antioxidants such as xanthones from mangosteen (Garcinia mangostana L.) show promise in protecting neurons from oxidative stress. Garcinone D's documented activation of the Nrf2/HO-1 pathway — seen in both neural stem cell and neuroprotection studies — is consistent with an antioxidant mechanism. Among the mangosteen xanthones studied for AD-related activities, α-Mangostin, Gartanin, Garcinone C, and γ-Mangostin showed better antioxidant properties to scavenge DPPH free radicals than Trolox. Garcinone D's own DPPH radical scavenging activity appeared less prominent than these congeners in that particular comparative study.
Evidence strength: Preclinical, primarily mechanistic (pathway activation) and in vitro assay data.
5. Body Systems and Health Areas of Association
- Oncology: Extracts and individual xanthones including those from mangosteen have been found to induce apoptosis and inhibit proliferation on cancer cells in vitro and in vivo. Garcinone D has demonstrated cytotoxic or growth-inhibitory activity against colon, breast, epidermoid, cervical, and small-cell lung cancer cell lines in in vitro settings.
- Central Nervous System / Neurodegeneration: Garcinone D has been studied in models relevant to Alzheimer's disease, including Aβ42-induced neurotoxicity, Aβ aggregation inhibition, BACE1 inhibition, and neural stem cell proliferation. All evidence is preclinical.
- Immune / Inflammatory System: Via NF-κB p65 inhibition and nitric oxide suppression in macrophage models, garcinone D has demonstrated anti-inflammatory potential in vitro.
- Endocrine (Estrogen Metabolism): Garcinone D has demonstrated aromatase-inhibitory activity in an enzyme-based assay; aromatase (CYP19A1) converts androgens to estrogens and is a therapeutic target in hormone-sensitive breast cancer.
- Gastrointestinal: Only addressed indirectly through the traditional ethnomedicinal use of mangosteen pericarp preparations for abdominal pain and diarrhea — no isolate-specific GI studies on garcinone D were identified in the literature.
6. Mechanisms of Action
The following mechanisms have been reported in the peer-reviewed literature for garcinone D specifically:
- NF-κB Inhibition: Garcinone D inhibited NF-κB p65 subunit activation with an IC₅₀ of 3.2 μM in an ELISA NF-κB assay, making it among the most potent NF-κB p65 inhibitors in its compound class from that study. NF-κB is a master regulator of inflammatory gene expression and cell survival pathways.
- Nrf2/HO-1 Pathway Activation: GD activates key antioxidant pathways involving Nrf2 and HO-1, and inhibits caspase activity. This activation was observed in both neuroprotection and neural stem cell proliferation contexts.
- STAT3/Cyclin D1 Pathway Activation: Garcinone D increased the protein levels of phosphorylated STAT3 (p-STAT3) and Cyclin D1 in concentration- and time-dependent manners in neural progenitor cells, suggesting a role in promoting cell cycle progression in that tissue type.
- Caspase Inhibition / Anti-Apoptotic Effects in Neurons: GD significantly enhances cell viability and stabilizes mitochondrial function while reducing reactive oxygen species and apoptotic markers in Aβ42-treated cells.
- β-Amyloid Aggregation Inhibition: Garcinone D was part of a series of xanthones exhibiting significant inhibition of self-induced β-amyloid (Aβ) aggregation and also β-site amyloid precursor protein-cleaving enzyme 1 (BACE1), and acting as potential antioxidants and biometal chelators.
- Aromatase Inhibition: In a noncellular, enzyme-based microsomal aromatase inhibition assay, garcinone D exhibited dose-dependent inhibitory activity.
- Nitric Oxide Suppression in Macrophages: Garcinone D showed potent NO-inhibitory effects in LPS-stimulated RAW264.7 macrophage cells.
7. Dosage Forms and Reported Dosages in Studies
Garcinone D has not been investigated in human clinical trials; all dosage information in the literature derives from in vitro assays or research compound preparations. The following concentrations have been explicitly reported in peer-reviewed sources:
- Aromatase inhibition (microsomal assay): Garcinone D had an IC₅₀ of 5.16 μM in a noncellular enzyme-based aromatase inhibition assay.
- NF-κB p65 inhibition (ELISA assay): Garcinone D inhibited NF-κB p65 activation with an IC₅₀ of 3.2 μM.
- HT-29 colon cancer cytotoxicity: Garcinone D (as compound 7) exhibited cytotoxicity against the HT-29 cell line with an ED₅₀ value of 9.1 μM.
- HeLa cervical cancer cytotoxicity: Garcinone D demonstrated an IC₅₀ value of 11.96 μM against HeLa cells.
- Neural stem cell proliferation: Garcinone D increased p-STAT3 and Cyclin D1 protein levels in concentration- and time-dependent manners in C17.2 cells; specific concentration ranges used were not extractable from available abstracts.
No recommended human dose, standardized extract concentration, or clinically validated dosing regimen for garcinone D as an isolated compound exists in the publicly available scientific literature. Any dosing of commercial mangosteen products containing garcinone D as part of the natural xanthone mixture is not equivalent to administration of isolated garcinone D.
8. Safety Considerations and Interactions
Absence of Human Safety Data for Garcinone D Specifically
No dedicated human safety studies, phase I dose-escalation trials, or toxicological assessments specific to isolated garcinone D have been identified in the peer-reviewed literature. All biological testing has been conducted in cell culture systems.
Whole-Mangosteen Product Safety Context
Because garcinone D is consumed — where it is consumed at all — as part of the total xanthone fraction of mangosteen pericarp products, the safety profile of those products provides relevant contextual information. A 30-day ingestion of a mangosteen-rich energy drink significantly increased antioxidant capacity and possessed anti-inflammatory benefits with no side effects on human hepatic and kidney functions in that particular study. However, this result pertains to the complex whole product and cannot be attributed specifically to garcinone D.
Aromatase Inhibition: Potential Hormonal Interaction
Because xanthones may be consumed in substantial amounts from commercially available mangosteen products, the consequences of frequent intake of mangosteen botanical dietary supplements require further investigation in the context of aromatase inhibition. Since aromatase converts androgens to estrogens, inhibition of this enzyme could theoretically affect endogenous estrogen levels, which may be relevant to populations with hormone-sensitive conditions or those taking hormonal medications. This remains a theoretical concern based on in vitro data, not a confirmed clinical effect.
Limited Clinical and Pharmacokinetic Data
Xanthones, including those from Garcinia mangostana, have shown potential neuroprotective effects due to their antioxidant, anti-inflammatory, and acetylcholinesterase inhibitory properties; however, their therapeutic use is limited by low bioavailability and restricted blood–brain barrier (BBB) penetration. Whether garcinone D specifically is subject to these pharmacokinetic limitations in humans has not been studied directly.
NF-κB Inhibition: Dual-Edge Mechanistic Consideration
Garcinone D's potent in vitro inhibition of NF-κB is a noteworthy mechanistic finding. NF-κB plays roles in both inflammatory disease pathology and in normal immune responses. Systemic NF-κB inhibition could theoretically impair immune surveillance, though this consideration applies only if a compound achieves physiologically relevant concentrations in vivo — something not established for garcinone D.
Evidence Status Summary
All experimental evidence for garcinone D is currently at the preclinical stage (in vitro cell culture systems and, in a limited way, for the broader mangosteen xanthone class, animal models). The plant is used locally in traditional medicine and has been promoted as an alternative cancer treatment, but clinical studies in humans are lacking. No regulatory body (FDA, EMA, EFSA, or similar) has issued a monograph or safety opinion specific to garcinone D as an isolated compound.
References
Go back